 |
2 Products |  |
0 Diseases | | 2 Products |
|
8 Trials |  |
3009 News |  |
| «1234567» |
- | Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Retrospective data, Journal: Clinical Efficacy of Infliximab in Patients With Crohn Disease in Different Locations of Disease Pathology: A Meta-Analysis. (Pubmed Central) - Oct 27, 2021
Our findings show different remission rates depending on location of the disease and may be useful for clinicians' choice of therapeutics.
- || Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients. (Pubmed Central) - Oct 22, 2021
An improvement in physical functioning of 7.3 ± 13.4 points (p = 0.002) with RAND/SF36 and in biomarker sIL-2R (-475.58 ± 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade or biosimilar infliximab Inflectra to biosimilar infliximab Flixabi did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission.
- | Journal: Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. (Pubmed Central) - Oct 20, 2021
The gain-share prescribing incentive has raised over €3.6 million for the specialties to invest back into patient care. Conclusion Against the background of a finite healthcare budget, this study shows that increasing use of biosimilars can create the financial savings and space to invest in new innovative therapies for the benefit of many patients.
- ||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical: A new study by Cleveland Clinic physicians comparing the biologic compound infliximab with the biosimilar infliximab-abda shows that the two therapies are comparable in both safety and efficacy. @RuthvikPadival and @tqaziMD discuss. #DDW2021 #IBD https://t.co/locWeQLOmw (Twitter) - Oct 17, 2021
- | Journal: Ozanimod (Zeposia) for ulcerative colitis. (Pubmed Central) - Oct 7, 2021
Conclusion Against the background of a finite healthcare budget, this study shows that increasing use of biosimilars can create the financial savings and space to invest in new innovative therapies for the benefit of many patients. No abstract available
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Infusion-related angioedema associated with infliximab-abda: Case report. (Pubmed Central) - Oct 1, 2021
Discontinuation of the biosimilar product along with supportive care brought about resolution of angioedema. There are no prior published reports of infusion-related angioedema reactions secondary to infliximab-abda use.
- || Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Reimbursement, Journal, Medicare: Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. (Pubmed Central) - Oct 1, 2021
Formulary placement of infliximab biologic and biosimilars in Medicare Part D is not optimized to generate cost savings for the Medicare program and beneficiaries, whose cost sharing is often based on the drug's list price. The Medicare program should provide incentives for PDPs to expand biosimilar coverage.
- | Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Retrospective data, Journal: Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis. (Pubmed Central) - Oct 1, 2021
ACR20 response appears to be comparable and nonsignificantly different between infliximab biosimilars. In the absence of any meaningful differences in safety or efficacy, biosimilar cost may be the deciding factor in choosing a treatment or agent for formulary inclusion.
- || Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar. (Pubmed Central) - Sep 24, 2021
In the absence of any meaningful differences in safety or efficacy, biosimilar cost may be the deciding factor in choosing a treatment or agent for formulary inclusion. No abstract available
- | Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center. (Pubmed Central) - Sep 24, 2021
No abstract available The probability of switching from iETN to bETN was likely related to physician characteristics.
- Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
[VIRTUAL] A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1124;
The probability of switching from iETN to bETN was likely related to physician characteristics. These are the first real-world data on SB4 in a routine setting in Greece, indicating that the majority of patients in this study cohort demonstrated clinically meaningful improvement in their physical function and disease activity by 24 and 52 weeks post-initiation of SB4 for treatment of RA.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
New trial, Real-world evidence, Real-world: SWEFOT-RWEM: Real-World Emulation of the SWEFOT Trial (clinicaltrials.gov) - Sep 21, 2021
P=N/A, N=509, Completed, Sponsor: Karolinska Institutet
- Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Payor-Mandated Non-Medical Switching From Infliximab to Biosimilar Creates Dosing Delays (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2811;
Sixty-two (8%) patients underwent a payor-mandated non-medical switch to biosimilar (59 infliximab-axxq, 2 infliximab-abda, 1 infliximab-dyyb). Dose and frequency remained the same as originator infliximab for all but one patient whose frequency was increased following bowel resection surgery.
- | Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
New P2 trial, Adverse events, Combination therapy, Metastases: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (clinicaltrials.gov) - Sep 5, 2021
P2, N=36, Not yet recruiting, Sponsor: Massachusetts General Hospital
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Clinical, Clinical data, Journal: Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. (Pubmed Central) - Aug 31, 2021
IP-10 and CXCL-9 declines were strongly correlated among patients with lymphopenia reversal (Day 3, Pearson r: 0.98, P-value 0.0006). Infliximab-abda may rapidly abrogate pathological inflammatory signaling to facilitate clinical recovery in severe and critical COVID-19.
- || Erelzi (etanercept biosimilar) / Novartis, Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical, Journal: Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. (Pubmed Central) - Aug 22, 2021
Infliximab-abda may rapidly abrogate pathological inflammatory signaling to facilitate clinical recovery in severe and critical COVID-19. No abstract available
- || Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Thank you. How about the timing of the two shots related to Renflexis infusion every 8 weeks? (Twitter) - Aug 19, 2021
- || Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Enrollment closed: PERFUSE: One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study (clinicaltrials.gov) - Aug 9, 2021
P=N/A, N=2274, Active, not recruiting, Sponsor: Biogen
No abstract available Recruiting --> Active, not recruiting
- || Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. (Pubmed Central) - Aug 4, 2021
Recruiting --> Active, not recruiting Switching from CT-P13 to SB2 seems to be safe and effective either in patients with a single than in those with multiple switches.
- | Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Journal: Recurrence rates of inflammation after switching from originator infliximab to biosimilar infliximab-abda for non-infectious uveitis. (Pubmed Central) - Jul 28, 2021
Providers should closely observe patients who switch to biosimilar infliximab, especially within the first 90 days. Those who do flare after switching may achieve quiescence with increased biosimilar dosing.
- || Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study. (Pubmed Central) - Jul 27, 2021
At our site, the incidence of IR was low, and PM did not decrease the incidence of IR in pediatric patients with IBD receiving IFX. These results indicate that PM with steroids should not be a standard part of IFX infusion to prevent IR.
- Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4506;
This analysis indicates that patients with IBD can be successfully and safely transitioned from reference or biosimilar IFX to SB2 with no loss of disease control, and no immunogenicity signal in naïve or transitioned patients, up to 24 months after initiation of SB2. Over 87% of transitioned patients continued SB2 treatment at M24 post-initiation.
- Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2326;
This analysis indicates that patients with IBD can be successfully and safely transitioned from reference or biosimilar IFX to SB2 with no loss of disease control, and no immunogenicity signal in naïve or transitioned patients, up to 24 months after initiation of SB2. Over 87% of transitioned patients continued SB2 treatment at M24 post-initiation.
- Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_495;
This analysis indicates that patients with IBD can be successfully and safely transitioned from reference or biosimilar IFX to SB2 with no loss of disease control, and no immunogenicity signal in naïve or transitioned patients, up to 24 months after initiation of SB2. Over 87% of transitioned patients continued SB2 treatment at M24 post-initiation.
- || Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. (Pubmed Central) - Jul 13, 2021
Overall, our data show that most of the patients switching from Infliximab originator to SB2 maintain the clinical and biochemical remission for at least 1 year. Further data are necessary to understand the clinical implications of these findings in the long term.
- | Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Journal: Statistical Equivalence Testing of Higher-Order Protein Structures with Differential Hydrogen Exchange-Mass Spectrometry (HX-MS). (Pubmed Central) - Jun 30, 2021
Application of the TOST-MDTE test on differential HX-MS measurements of wild-type and mutated maltose-binding proteins demonstrates that the equivalence testing method was fit-for-purpose. Three infliximab biosimilars (Remsima, Renflexis, and Inflectra) were found to be equivalent to their Remicade reference product based on differential HX-MS measurements, while 5% deglycosylated NIST mAb was not statistically equivalent to the unmodified NIST mAb reference.
- || Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma
Clinical, Journal: Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. (Pubmed Central) - Jun 22, 2021
P3
In this pooled analysis of phase III clinical trial data of biosimilars for RA, identifiable baseline factors (SJC28, CRP, and PhGA) associated with radiographic progression were similar to those described in prior studies. Even though radiographic progression was minimal, a small number of patients who have increased SJC28, CRP, and PhGA at baseline should be closely monitored and follow treat-to-target approach.
- ||||| Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical: A new study by Cleveland Clinic physicians comparing the biologic compound infliximab with the biosimilar infliximab-abda shows that the two therapies are comparable in both safety and efficacy. @RuthvikPadival and @tqaziMD discuss. #DDW2021 #IBD https://t.co/locWeQLOmw (Twitter) - Jun 19, 2021
- || Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
Clinical, Journal: Identification of QTLs for Spot Blotch Resistance in Two Bi-Parental Mapping Populations of Wheat. (Pubmed Central) - Jun 3, 2021
The identified QTLs upon stacking showed an additive effect in lowering the SB score in both populations. The probable presence of newly identified Sb4 and durable resistance gene Lr46 in the identified QTL regions indicates the importance of these genes in breeding for SB resistance in Bangladesh and the whole of South Asia.
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] A SURVEY OF RHEUMATOLOGY PATIENTS’ SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS () - May 21, 2021 - Abstract #EULAR2021EULAR_3790;
Only 28% of the patients found the new device difficult to use. Overall conclusion from the study showed less than one quarter of the participants showed dissatifaction towards biosimilar and less than 12 % experienced systemic side effects and whether biosimilar could be a next cost effective biologic therapy to replace originator in future requires a longer duration of study.
- [VIRTUAL] SEVERE BREAST ULCERATION IN BEHÇET’S DISEASE TREATED WITH CYCLOPHOSPHAMIDE: A CASE REPORT () - May 21, 2021 - Abstract #EULAR2021EULAR_3729;
Similar presentations in Behcet’s disease have been recognised 2 , although much less commonly. Our case demonstrates that severe breast ulceration can be a clinical manifestation of this condition and can be refractory to usual therapies.
- Erelzi (etanercept biosimilar) / Novartis
[VIRTUAL] NON MEDICAL SWITCH FROM ETANERCEPT ORIGINATOR TO BIOSIMILAR GP2015 IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES () - May 21, 2021 - Abstract #EULAR2021EULAR_1992;
In literature, several evidences from clinical trials and registry studies showed that the switch from etanercept originator to biosimilar SB4 was safe [1]. Our study confirmed that the NMS from ETN originator to GP2015 represents a safe practice that maintains the efficacy of the current treatment.
- Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NONINTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; 12-MONTH ANALYSIS (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2072;
Over 56% of IFX- naïve patients and over 79% of patients transitioned from prior IFX remained on SB2 at 12 months post-initiation. With follow-up of patients ongoing to 24 months post-initiation of SB2, the study will continue to provide pertinent information about clinical outcomes of initiation on SB2 as first IFX or after transition from reference or IFX biosimilar to SB2.
- Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
[VIRTUAL] EXPLORING EQUIVALENCE BETWEEN BIOSIMILAR SB4 AND REFERENCE ETANERCEPT BY ASSESSING EFFECTIVENESS IN RHEUMATOID ARTHRITIS PATIENTS TREATED IN ORDINARY CLINICAL PRACTICE (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2071;
A conventional regression model may not fully account for differences in key clinical measures (in this instance, disease activity) between the two groups at baseline, and therefore the Week 52 results might be biased. The propensity score matched model ensures comparability of the groups at baseline and therefore the validity of the Week 52 results should be more robust.
- Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2066;
Despite their identical indications and therapeutic positioning, there are some differences in the baseline characteristics between patients who start ADA, IFX and RIT and their biosimilars. There are no differences in drug survival between originator and biosimilar with the possible exception of etanercept although the observed difference should be interpreted in light of possible unmeasured or residual channeling.
- Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
[VIRTUAL] MODELLING OF DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY ARTHROPATHIES TREATED WITH ETANERCEPT ORIGINATOR OR BIOSIMILAR AS FIRST-LINE BIOLOGIC IN AN AUSTRALIAN REAL-WORLD DATASET (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2051;
Persistence on treatment was not different between the two drugs. Respondent characteristics.
- Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
[VIRTUAL] INCIDENCE AND DETERMINANTS ASSOCIATED WITH RETRANSITIONING FROM BIOSIMILAR SB4 TO ORIGINATOR ETANERCEPT (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2039;
These patients might be identified prior to retransitioning based on their contacts to the rheumatology department. Information specifically aiming for their concerns might prevent them from retransitioning.
- || Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. (Pubmed Central) - May 15, 2021
CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical efficacy and safety in patients with Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis.
- || Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
Clinical, Journal, Real-world evidence: Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (Pubmed Central) - May 4, 2021
Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical efficacy and safety in patients with Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis. Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life.
- || Zarzio (filgrastim biosimilar) / Novartis, Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, P4 data, Journal: Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness. (Pubmed Central) - Apr 27, 2021
Use of biosimilar filgrastim has increased in the United States, but infliximab biosimilar use remains low. Data on identification of biosimilars in claims data and observed gaps between exposure episodes can be used to support drug safety studies of biosimilars.
- | Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung, Mundipharma
Retrospective data, Journal: Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. (Pubmed Central) - Apr 20, 2021
P3
Data on identification of biosimilars in claims data and observed gaps between exposure episodes can be used to support drug safety studies of biosimilars. A pooled analysis of radiographic assessment data from three biosimilar studies showed that radiographic progression is small overall but increases with worse disease activity.
- || Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
Clinical, Journal: Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. (Pubmed Central) - Apr 20, 2021
A pooled analysis of radiographic assessment data from three biosimilar studies showed that radiographic progression is small overall but increases with worse disease activity. Double switching from the originator Infliximab to CT-P13 and then to SB2 was not associated with an impairment in patient beliefs, while the effectiveness, immunogeniity and safety of anti-TNF therapy remained stable after 54 weeks of follow-up.
- Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] Comparison of treatment patterns following initiation of Renflexis, Inflectra, or Remicade () - Apr 17, 2021 - Abstract #AMCP2021AMCP_351;
Double switching from the originator Infliximab to CT-P13 and then to SB2 was not associated with an impairment in patient beliefs, while the effectiveness, immunogeniity and safety of anti-TNF therapy remained stable after 54 weeks of follow-up. Awaiting results
- || Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
Clinical, Journal, Real-world evidence: BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis. (Pubmed Central) - Apr 15, 2021
Awaiting results Transition from reference etanercept to SB4 is effective and safe in patients with stable RA and axSpA.
- Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] Outcomes with Infliximab and Its Biosimilars in Patients with Rheumatoid Arthritis (RA)- Real-World Experience in the US () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_80;
In LR variables significantly associated the outcome were baseline disease activity (high/moderate vs low/remission: adjusted odds ratio (OR)=.09 CI .07-.14), payer type (Medicaid vs commercial: OR=.47 CI=.22-.99, and use of steroids (OR=.56 CI .40-.79) but not choice of a biologic (infliximab-abda vs infliximab OR=.91 CI .49-1.69, infliximab-dyyb vs infliximab OR=1.11 CI .74-1.65). CONCLUSIONS After accounting for patient characteristics, regimen choice was not significantly associated with treatment success at 6 months since regimen initiation.
- | Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
Journal: Air quality measurements in four sheep barns part II: pollutant gas emissions. (Pubmed Central) - Apr 10, 2021
The average NH and CH emissions from each barn were 2.1 and 2.7 kg day barn for SB1; 9.4 and 12.9 kg day barn for SB2; 4.0 and 3.6 kg day barn for SB3; and 4.5 21 kg day barn for SB4, respectively...These models can only be used in the Bursa region. The results of this study were compared with other studies under similar conditions in the literature.
- | Enrollment open: NeuMRA: Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients (clinicaltrials.gov) - Apr 8, 2021
P=N/A, N=212, Recruiting, Sponsor: Vastra Gotaland Region
The results of this study were compared with other studies under similar conditions in the literature. Not yet recruiting --> Recruiting
- Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] CLINICAL AND BIOCHEMICAL EFFICACY ARE NOT AFFECTED BY SWITCH FROM INFLIXIMAB ORIGINATOR TO RENFLEXIS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS. () - Mar 25, 2021 - Abstract #CDDW2021CDDW_149;
To date, there is limited pediatric IBD data demonstrating that switching from IFX originator to IFX biosimilar CT-P13 is safe and effective, and no data on switching to Renflexis. Pediatric IBD patients can be successfully switched from IFX originator to biosimilar Renflexis during maintenance without affecting efficacy, immunogenicity or safety in the short term.
- | Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan, Biogen, Mundipharma
Retrospective data, Journal: Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study. (Pubmed Central) - Mar 16, 2021
Being the development of biosimilars a significant opportunity to decrease medical care cost and increase treatment options (3), extrapolation of clinical data from other indications determined an intense scientific debate on the interchangeability between originator and biosimilar in real-life, and recently reports on efficacy and safety of the biosimilar SB4 in plaque-type psoriasis have been published (4, 5). The aim of our observational, retrospective, single-center, study was to investigate the etanercept biosimilar SB4 in patients affected by plaque-type psoriasis and PsA.
- Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
[VIRTUAL] BIOSIMILAR SWITCH IN A LARGE QUATERNARY CARE AMERICAN MEDICAL INSTITUTION DOES NOT RESULT IN WORSENING OF INFLAMMATORY BOWEL DISEASE ACTIVITY (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3445;
There was no difference in IBD disease activity or utilization of medical services in patients who underwent a non-medical switch from originator infliximab to the biosimilar infliximab-abda at a large quaternary medical center. Consequently, there was a similar efficacy and safety profile between originator infliximab and biosimilar infliximab-abda in this real-world comparison.